ALK and adenocarcinoma: ALK translocation (41%)EGFR mutations (30%)KRAS mutations (2%)Young patients having adenocarcinoma without GA associated with worse overall survival compared to old patients without GA (8.9 versus 16.4 months, p<0.001)